Literature DB >> 35239963

Enhancing demethylation-induced differentiation in IDH-mutant glioma.

Julie J Miller1,2, Daniel P Cahill2,3, Isabel Arrillaga-Romany1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35239963      PMCID： PMC9071324          DOI： 10.1093/neuonc/noac056

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  7 in total

1.  IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Authors:  Chao Lu; Patrick S Ward; Gurpreet S Kapoor; Dan Rohle; Sevin Turcan; Omar Abdel-Wahab; Christopher R Edwards; Raya Khanin; Maria E Figueroa; Ari Melnick; Kathryn E Wellen; Donald M O'Rourke; Shelley L Berger; Timothy A Chan; Ross L Levine; Ingo K Mellinghoff; Craig B Thompson
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

2.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

3.  Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas.

Authors:  Marina da Costa Rosa; Alex Shimura Yamashita; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 12.300

4.  Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.

Authors:  Alex Shimura Yamashita; Marina da Costa Rosa; Alexandra Borodovsky; William T Festuccia; Timothy Chan; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

5.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504

6.  5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

Authors:  Alexandra Borodovsky; Vafi Salmasi; Sevin Turcan; Armida W M Fabius; Gilson S Baia; Charles G Eberhart; Jon D Weingart; Gary L Gallia; Stephen B Baylin; Timothy A Chan; Gregory J Riggins
Journal:  Oncotarget       Date:  2013-10

7.  Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

Authors:  Sevin Turcan; Armida W M Fabius; Alexandra Borodovsky; Alicia Pedraza; Cameron Brennan; Jason Huse; Agnes Viale; Gregory J Riggins; Timothy A Chan
Journal:  Oncotarget       Date:  2013-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.